ORGANOGENESIS NAMES PRESIDENTOrganogenesis (ASE:ORG) of Cambridge, Mass., announced thatThomas M. Tully has been appointed president and chiefoperating officer, effective Aug. 1. He will also serve on theboard of directors. Tully had been president of Schneider Inc., asubsidiary of Pfizer Inc..
Dr. Barry W. Steiger has joined MGI Pharma Inc. (NASDAQ:MOGN), a Minneapolis developer and marketer ofpharmaceuticals, as vice president of medical affairs. Steiger,formerly vice president of clinical development at QuadraLogic Technologies Inc., will oversee MGI's clinicaldevelopment programs.
Biotechnology analyst Denise Gilbert, formerly with CountyNatWest Securities, has become a research analyst at SmithBarney. She will initiate investment coverage of severalbiotechnology companies.
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), a Tarrytown,N.Y., developer of treatments for neurodegenerative diseasesand nerve injuries, has appointed Fredric D. Price vicepresident of finance and administration and chief financialofficer. Price, former owner of RxFDP, an independent healthcare consulting practice, replaces Fred Middleton, who willremain on Regeneron's board of directors.
Debra Bannister has been appointed director of corporatecommunications for Synergen Inc. (NASDAQ:SYGN), a Boulder,Colo., developer of treatments for inflammatory diseases,chronic skin ulcers and neurological disorders. Bannister,formerly of the corporate and financial relations group forRegis McKenna Inc., will be responsible for investor, media andcommunity relations.
William W. Chorske has been named president of MedtronicEurope, a unit of Medtronic Inc. (NYSE:MDT), a Minneapolisdeveloper and manufacturer of biomedical devices forimproving cardiovascular and neurological health. Chorske,formerly Medtronic's chief financial officer, will remain acorporate senior vice president. He succeeds Gerard C.Planchon, who will continue as executive vice president ofglobal business.-- Jeff Hutkoff
(c) 1997 American Health Consultants. All rights reserved.